Stockscreener 앱 받기
446.40
0.71%
-3.18
시간 외 거래:
446.40
전일 마감가:
$449.58
열려 있는:
$453.045
하루 거래량:
814.45K
Relative Volume:
0.72
시가총액:
$58.51B
수익:
$2.46B
순이익/손실:
$-319.09M
주가수익비율:
-180.73
EPS:
-2.47
순현금흐름:
$-52.09M
1주 성능:
-1.58%
1개월 성능:
-1.06%
6개월 성능:
+65.82%
1년 성능:
+62.58%
1일 변동 폭
$442.51
$453.05
1주일 범위
$442.51
$462.88
52주 변동 폭
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
446.40 | 58.93B | 2.46B | -319.09M | -52.09M | -2.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
385.74 | 97.91B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.90 | 58.88B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
711.62 | 43.52B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.06 | 36.11B | 3.81B | -644.79M | -669.77M | -6.24 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
How Alnylam Pharmaceuticals' (ALNY) Entry to Genomic Data Alliance Could Shape Its Drug Pipeline Progress - simplywall.st
$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today - Benzinga
RNA-Based Therapies Industry Analysis 2025 | Growth, USA Market - openPR.com
Is Alnylam Pharmaceuticals (ALNY) an Undervalued Stock? - Insider Monkey
Does Alnylam Pharmaceuticals (ALNY) Have the Potential to Generate Strong Long-Term Growth? - Insider Monkey
Cardiac Amyloidosis Pipeline 2025: Pioneering Clinical Developments by 20+ Global Leaders – DelveInsight | Featuring Eidos Therapeutics, Intellia Therapeutics, Novo Nordisk, Alnylam Pharmaceuticals - Barchart.com
Why Alnylam Pharmaceuticals (ALNY) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Bannerman Wealth Management Group LLC Sells 565 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
IFM Investors Pty Ltd Acquires 1,508 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assenagon Asset Management S.A. Purchases 11,281 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Swedbank AB Has $20.97 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $500.00 at Royal Bank Of Canada - MarketBeat
Pallas Capital Advisors LLC Decreases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY): Evaluating Valuation After FDA Tightens Drug Advertising Disclosure Rules - simplywall.st
Alnylam at Bernstein Forum: Strategic Growth in RNAi Therapies - Investing.com
Alnylam at Bernstein Forum: Strategic Growth in RNAi Therapies By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals, Inc. $ALNY Shares Purchased by Sumitomo Mitsui DS Asset Management Company Ltd - MarketBeat
RNA-based Therapies Market to Reach USD 213.54 Billion by 2033, Driven by Rare Diseases, Oncology, and Advances in RNA Technologies | DataM Intelligence - PR Newswire
With DTC ads under fire, pharma companies need to pivot - PharmaVoice
U.S. Capital Wealth Advisors LLC Sells 3,984 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $520.00 - MarketBeat
Gateway Investment Advisers LLC Decreases Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $566.00 at The Goldman Sachs Group - MarketBeat
Aug Volume: Is Alnylam Pharmaceuticals Inc impacted by rising ratesQuarterly Profit Summary & Free Verified High Yield Trade Plans - خودرو بانک
Nasdaq Moves: What’s the fair value of Alnylam Pharmaceuticals Inc. stock2025 Market Overview & Growth Oriented Trading Recommendations - خودرو بانک
Does Alnylam's Entry Into the Genomics Alliance Hint at a New Era for Illumina (ILMN) R&D? - Yahoo Finance
Swedbank AB Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Fed Meeting: Is Alnylam Pharmaceuticals Inc impacted by rising ratesEarnings Miss & AI Powered Buy and Sell Recommendations - خودرو بانک
Performance Recap: Can Alnylam Pharmaceuticals Inc. be the next market leader2025 Top Gainers & Real-Time Chart Pattern Alerts - khodrobank.com
Strs Ohio Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Acadian Asset Management LLC Has $2.42 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
RBC Capital Initiates Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $500 - 富途牛牛
Alnylam stock price target raised to $500 from $435 at RBC Capital - Investing.com India
Alnylam Pharmaceuticals Completes Phase 1 Study of ALN-AGT01 RVR - TipRanks
Moderna, Alnylam settle patent row over COVID vaccine delivery technology - MSN
RBC Capital Raises Alnylam Pharmaceuticals (ALNY) Price Target t - GuruFocus
Moderna (MRNA) Settles Patent Dispute with Alnylam - GuruFocus
RBC Raises Price Target on Alnylam Pharmaceuticals to $500 From $435, Keeps Outperform Rating - MarketScreener
Ascent Group LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $3.76 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
AG2R LA Mondiale Gestion D Actifs Buys New Shares in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Growth Review: What are analysts price targets for Alnylam Pharmaceuticals IncJuly 2025 Levels & Free Weekly Watchlist of Top Performers - khodrobank.com
Coagulation factor deficiency Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Novo Nordisk, Pfizer, Spark Therapeutics, Roche, Sanofi (Genzyme), Alnylam Pharmaceuticals - Barchart.com
Moderna settles Alnylam patent lawsuits over COVID vaccine technology - ET Pharma
Moderna settles Alnylam patent lawsuits over COVID vaccine technology | Business Information & News | FE - Westlaw Today
Moderna, Alnylam Agree to End Vaccine-Delivery Patent Lawsuits - Bloomberg Law News
Alnylam joins genomic alliance to advance RNA interference therapies - Investing.com India
Alnylam joins Alliance for Genomic Discovery to advance RNAi therapeutics - Drug Discovery News
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - The Malaysian Reserve
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, ex - GuruFocus
Alnylam Pharmaceuticals Insiders Sold US$12m Of Shares Suggesting Hesitancy - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.51%
0.81%
자본화:
|
볼륨(24시간):